April 27, 2023 10:47 AM EDTUpdated April 28, 02:53 PM
Deals
Diagnostics

Quest Di­ag­nos­tics buys Bert Vo­gel­stein’s Haystack On­col­o­gy, just six months af­ter Se­ries A

Lei Lei Wu

News Reporter

Quest Di­ag­nos­tics is buy­ing can­cer de­tec­tion start­up Haystack On­col­o­gy for $300 mil­lion in cash, with plans to launch a new can­cer lab test in 2024 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times